RJA
ALXN

Raymond James & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Raymond James & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,300
Closed -$7K – 3751
2018
Q4 		$7K Buy
+11,300
New +$1.34M ﹤0.01% 3482

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Raymond James & Associates's ALXN Position: Q3 2021 in Review

Raymond James & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 30,808 shares — an estimated $5.66M sold.

Raymond James & Associates first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $39.9M in Q3 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Raymond James & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 30,808 Alexion Pharmaceuticals shares in Q3 2021, an estimated $5.66M.
  • Raymond James & Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Raymond James & Associates's Alexion Pharmaceuticals position peaked at $39.9M in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.